This article is discussing psyc meds, but it applies to all generics.
"Janicak explained that Food and Drug Administration (FDA) requirements around bioequivalence of generic products are fairly strict: a generic must have between 80 percent and 125 percent bioequivalency to its name-brand product—a window of 20 percent less or 25 percent greater potency." (6th paragraph)
Physicians Question FDA's Confidence in Generic Drugs' Safety, Efficacy-
psychnews.psychiatryonline.org/newsArticle.aspx?articleid=110993